Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance

Hani Hassoun; Mikhail Roshal; Joshua Sabari; James Nguyen; Qi Gao; Sean M Devlin; Heather Landau; Nikoletta Lendvai; David J Chung; Alexander M Lesokhin; Neha Korde; Sham Mailankody; Ahmet Dogan; Sergio A Giralt; C Ola Landgren

doi:10.1080/10428194.2017.1312382

Back

Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance

Journal article

Peer reviewed

Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance

Hani Hassoun, Mikhail Roshal, Joshua Sabari, James Nguyen, Qi Gao, Sean M Devlin, Heather Landau, Nikoletta Lendvai, David J Chung, Alexander M Lesokhin, …

Leukemia & lymphoma, Vol.58(12), pp.2962-2965

2017-12

DOI: https://doi.org/10.1080/10428194.2017.1312382

PMID: 28482750

Abstract

Antineoplastic Combined Chemotherapy Protocols - adverse effects

Antineoplastic Combined Chemotherapy Protocols - therapeutic use

Biomarkers

Hematopoietic Stem Cell Transplantation - adverse effects

Hematopoietic Stem Cell Transplantation - methods

Humans

Immunophenotyping

Lenalidomide

Leukemoid Reaction - diagnosis

Leukemoid Reaction - etiology

Multiple Myeloma - complications

Multiple Myeloma - therapy

Plasma Cells - pathology

Thalidomide - adverse effects

Thalidomide - analogs & derivatives

Thalidomide - therapeutic use

Metrics

2 Record Views

2 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Citation topics: 1 Clinical & Life Sciences; 1.130 Lymphomas; 1.130.617 Multiple Myeloma
Web Of Science research areas: Hematology; Oncology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance
Creators: Hani Hassoun - Memorial Sloan Kettering Cancer Center
Mikhail Roshal - Memorial Sloan Kettering Cancer Center
Joshua Sabari - Memorial Sloan Kettering Cancer Center
James Nguyen - Memorial Sloan Kettering Cancer Center
Qi Gao - Memorial Sloan Kettering Cancer Center
Sean M Devlin - Memorial Sloan Kettering Cancer Center
Heather Landau - Memorial Sloan Kettering Cancer Center
Nikoletta Lendvai - Memorial Sloan Kettering Cancer Center
David J Chung - Memorial Sloan Kettering Cancer Center
Alexander M Lesokhin - Memorial Sloan Kettering Cancer Center
Neha Korde - Memorial Sloan Kettering Cancer Center
Sham Mailankody - Memorial Sloan Kettering Cancer Center
Ahmet Dogan - Memorial Sloan Kettering Cancer Center
Sergio A Giralt - Memorial Sloan Kettering Cancer Center
C Ola Landgren - Memorial Sloan Kettering Cancer Center
Publication Details: Leukemia & lymphoma, Vol.58(12), pp.2962-2965
Grant note: P30 CA008748 / NCI NIH HHS
Academic Unit: Miller School of Medicine; UMMG Department of Medicine
Language: English
Resource Type: Journal article
PMID: 28482750
Record Identifier: 991031713781802976